Adaptimmune And Astellas Team Up For Off-The-Shelf T-Cell Therapies

Could Be Worth $900m

 
• By Kevin Grogan
  
Suit_Battery
Data boost and Astellas Deal Revitalize Adaptimmune • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer